Most hypothyroidism treatment in the United States starts and stays with levothyroxine — synthetic T4. For many patients, it works well. For others, normal lab values coexist with persistent fatigue, brain fog, and weight difficulties that do not resolve on T4 alone. Understanding the difference between T3 and T4 — and the options between them — is the starting point for any informed conversation with a provider.
Note: Compounded thyroid medications are not FDA-approved and are prepared under federal compounding regulations. Any protocol change should occur under the supervision of a licensed provider. Approval is not guaranteed.
How T3 and T4 Work
Your thyroid gland produces two primary hormones: thyroxine (T4) and triiodothyronine (T3). Despite both being called "thyroid hormones," they are not equally active.
T4 is a prohormone. It circulates in the bloodstream and is converted to T3 primarily in the liver, kidneys, and other peripheral tissues by enzymes called deiodinases. T4 itself has minimal direct activity at thyroid receptors.
T3 is the active hormone. It directly binds thyroid hormone receptors in cells, driving the metabolic effects associated with thyroid function: energy production, body temperature regulation, heart rate, cognitive speed, and more. T3 is approximately three to four times more potent than T4 at the receptor level.
When you take levothyroxine (T4), you are supplying the raw material. Your body must convert it. How efficiently that conversion happens varies by individual — and that variability is central to why some patients do not feel well on T4-only therapy.
Why T4-Only Therapy Does Not Work for Every Patient
The standard treatment paradigm — normalize TSH with levothyroxine — works for the majority. However, a meaningful subset of hypothyroid patients report ongoing symptoms despite TSH within range. Several mechanisms have been proposed:
- Impaired T4-to-T3 conversion: Variants in the DIO2 gene (encoding deiodinase type 2) are associated with reduced T3 production from T4, particularly in the brain. Research has found that individuals with certain DIO2 polymorphisms may respond better to combination therapy.
- Tissue-level T3 insufficiency: Serum T3 may normalize while intracellular T3 in specific tissues (notably the brain) remains suboptimal.
- Patient preference and quality of life: A 2019 patient preference study (PMC6667836) found that when given blinded trials of T4-only versus combination T4+T3, a significant proportion of patients preferred combination therapy and reported better mood and general well-being.
Head-to-Head Comparison
| Feature | T4 Only (Levothyroxine) | T3 Only (Liothyronine) | T4+T3 Combination | Desiccated Thyroid Extract (DTE) |
|---|---|---|---|---|
| Active form | Prohormone (requires conversion) | Active (direct receptor binding) | Both prohormone + active | Both (fixed ratio) |
| Half-life | ~7 days | ~1–2 days | Varies by formulation | Varies by component |
| Dosing frequency | Once daily | Once to twice daily | Once or split daily | Once to twice daily |
| FDA-approved status | Yes (commercial) | Yes (commercial Cytomel); compounded = not approved | Compounded = not approved | Yes (Armour, NP Thyroid); compounded DTE = not approved |
| Customizable ratio | N/A | N/A | Yes (compounded) | No (fixed ~4:1 T4:T3) |
| Typical use case | First-line hypothyroidism | T3 supplementation, thyroid cancer monitoring | Persistent symptoms on T4-only | Patient preference, whole-gland approach |
What the Research Shows
Guidelines from major endocrinology societies — including the American Thyroid Association — have historically recommended T4 monotherapy as the standard of care, with combination therapy reserved for select cases. However, the evidence is evolving.
A 2024 meta-analysis (PMC11177353) pooled data from randomized controlled trials comparing T4 monotherapy to T4+T3 combination and found:
- Standard thyroid labs (TSH, free T4) were similar between groups.
- A subset of patients on combination therapy reported improved quality of life, mood, and cognitive function.
- The benefit was more consistent in subgroup analyses of patients with prior thyroidectomy and those with DIO2 gene variants.
- No significant increase in adverse cardiac events was observed at standard doses in the trials reviewed.
The meta-analysis concluded that while combination therapy should not be universally recommended, individualized use is warranted for patients who remain symptomatic on optimized T4-only therapy.
What Is Desiccated Thyroid Extract (DTE)?
Desiccated thyroid extract is derived from porcine (pig) or bovine (cow) thyroid glands and contains both T4 and T3 in a naturally occurring ratio of approximately 4:1. Commercial brand names include Armour Thyroid and NP Thyroid; these are FDA-approved products.
DTE differs from compounded combinations in one important way: the T4:T3 ratio is fixed. Some patients and providers prefer this; others find they need a customized ratio that commercial DTE cannot provide. Compounded DTE and customized compounded T4+T3 combinations are not FDA-approved.
Who Might Benefit from T3 or Combination Therapy?
T3-inclusive therapy is not appropriate for every hypothyroid patient. Providers typically consider it when:
- TSH is consistently within the reference range but symptoms persist (fatigue, cognitive slowing, mood changes, unexplained weight difficulty)
- Free T3 is low-normal relative to free T4, suggesting conversion inefficiency
- Prior thyroidectomy has removed the gland’s native contribution to T3 production
- The patient has documented DIO2 gene variants associated with reduced T4-to-T3 conversion
- Adequate trial of T4-only at optimized dose has not produced symptom resolution
This is a clinical decision that requires a full review of labs, symptoms, medication history, and cardiovascular history. T3 has a shorter half-life and more rapid receptor action than T4; dosing errors carry a different risk profile.
Compounded vs. Commercial Thyroid Preparations
Commercial preparations (levothyroxine, Cytomel, Armour Thyroid) are FDA-approved and subject to standardized manufacturing. Compounded thyroid preparations — including customized T4+T3 dosing or sustained-release T3 formulations — are not FDA-approved and are prepared under federal compounding regulations.
Compounding allows ratio and dosing customization that commercial products cannot provide. This is why some providers prescribe compounded preparations for patients who have not responded to standard options. However, the absence of FDA approval means these preparations have not undergone the same pre-market efficacy and safety review as approved drugs.
At TelosRX, our asynchronous evaluation process allows a licensed provider to review your full thyroid history, current labs, and symptom profile without requiring a real-time appointment. Compounded thyroid protocols are available subject to provider approval — approval is not guaranteed. Browse our hormone optimization protocols to learn what evaluations are available.
Frequently Asked Questions
What is the difference between T3 and T4 thyroid medication?
T4 (levothyroxine) is a storage hormone that must be converted to T3 to become biologically active. T3 (liothyronine) is the active form that directly binds thyroid hormone receptors. T4-only therapy relies on your body's conversion capacity; T3 or combination therapy bypasses that step.
Why do some patients feel better on T3 or combination therapy?
Some individuals have reduced activity of the enzyme that converts T4 to T3 in tissues. For these people, T4-only therapy may normalize lab values while leaving tissue-level T3 insufficient. Patient preference studies show a subset report improved quality of life on combination T4+T3.
Is T3 medication FDA-approved?
Liothyronine (T3) is FDA-approved in its commercial form (Cytomel). Compounded T3, compounded T4+T3 combinations, and compounded desiccated thyroid preparations are not FDA-approved and are prepared under federal compounding regulations.
What does the research say about T4+T3 combination therapy?
A 2024 meta-analysis (PMC11177353) found that a subset of patients reported improved quality of life and mood on combination therapy compared to T4-only, though standard thyroid labs were similar between groups. Guidelines support individualized use for patients who remain symptomatic on optimized T4 monotherapy.
What is desiccated thyroid extract (DTE)?
DTE is derived from porcine or bovine thyroid glands and contains both T4 and T3 in a fixed ratio of approximately 4:1. Commercial DTE brands like Armour Thyroid are FDA-approved. Compounded DTE is not FDA-approved.
Can I get T3 or combination thyroid therapy at TelosRX?
TelosRX offers asynchronous thyroid evaluations. Compounded thyroid protocols, including T3 and customized T4+T3 combinations, are available subject to approval by a licensed provider. Compounded preparations are not FDA-approved. Approval is not guaranteed.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.